RTS,S/AS01E疟疾疫苗在加纳和肯尼亚幼儿中采用全剂量或分次剂量方案随访50个月的持续效力:开放标签2b期随机对照试验最终结果
在加纳和肯尼亚两个研究中心开展的开放标签2b期随机对照试验,5-17月龄儿童随机分为5组,分别接种狂犬病疫苗或不同RTS,S方案,随访至50个月。所有RTS,S方案对临床疟疾均有保护效力,额外年度剂量可维持效力和影响至50个月,分次剂量方案可增加疫苗可及性并降低成本。
要点
- RTS,S各方案至50个月对临床疟疾的疫苗效力分别为36%、51%、43%和41%,均p<0·001。
- 每1000剂RTS,S全剂量当量避免的病例数在分次剂量组较高(1151和1134)。
- 疫苗耐受性良好,仅5例严重不良事件被认为与接种相关,无与接种相关的死亡。
核心结论
- 所有RTS,S方案均对临床疟疾提供实质性保护,额外年度剂量维持疫苗效力和影响至50个月。
- 使用分次剂量方案可增加RTS,S的可及性并降低接种成本。
研究设计与样本
- 开放标签、随机对照2b期试验,在加纳Agogo和肯尼亚Siaya县两个研究中心开展,时间为2017年9月28日至2022年11月14日。
- 5-17月龄儿童按1:1:1:1:1随机分为5组:对照组接种狂犬病疫苗;R012-20组在第0、1、2月接种全剂量RTS,S后第20月接种全剂量;R012-14-26-38组在第0、1、2月接种全剂量后第14、26、38月接种全剂量;Fx012-14-26-38组第0、1月接种全剂量后第2、14、26、38月接种分次剂量(全剂量的五分之一);Fx017-20-32组第0、1月接种全剂量后第7、20、32月接种分次剂量。
- 2017年9月28日至2018年9月25日共入组2157名儿童,其中1609名随机分配(每个RTS,S组322名,对照组321名);1609名中1500名至少接种一剂研究疫苗(暴露集),1333名纳入符合方案集用于效力分析。
- 试验注册号ClinicalTrials.gov NCT03276962,已完成。
主要发现
- 在暴露集儿童中,至第50个月,R012-20组、R012-14-26-38组、Fx012-14-26-38组和Fx017-20-32组对全部临床疟疾发作的疫苗效力分别为36%(95%CI 19-50)、51%(37-61)、43%(28-55)和41%(26-53),所有组p<0·001。
- 每1000剂RTS,S全剂量当量避免的病例数分别为:R012-20组353例,R012-14-26-38组544例,Fx012-14-26-38组1151例,Fx017-20-32组1134例。
- 在第四剂后接受额外疫苗剂量的组中,疫苗效力、影响和免疫反应在50个月随访期间维持。
- 疫苗耐受性良好;仅5例严重不良事件被认为与接种相关;无与接种相关的死亡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We conducted a phase 2b trial evaluating fractional-dose and full-dose regimens of the RTS,S/AS01E vaccine (RTS,S). All regimens provided substantial protection against clinical malaria in natural exposure settings, over 21 and 32 months of follow-up. Here, we present end-of-study results, after 50 months of follow-up. METHODS: This open-label, randomised controlled trial was conducted at two research centres in Agogo (Ghana) and Siaya County (Kenya) between Sept 28, 2017, and Nov 14, 2022. Children aged 5-17 months were randomly assigned (1:1:1:1:1) to one of five groups to receive rabies vaccine (the control group) at months 0, 1, and 2; or full doses of RTS,S at months 0, 1, and 2, followed by either full doses (R) at month 20 (group R012-20) or months 14, 26, and 38 (R012-14-26-38); or full doses at months 0 and 1, followed by fractional doses (Fx; one-fifth of full dose) at months 2, 14, 26, and 38 (Fx012-14-26-38) or months 7, 20, and 32 (Fx017-20-32). We present results of secondary objectives, evaluating vaccine efficacy, impact, immunogenicity, and harms up to month 50. Endpoints were the occurrence of clinical malaria meeting the primary and secondary case definitions and antibody responses at predefined timepoints, and the occurrence of solicited adverse events within 7 days from vaccination and serious adverse events and adverse events of special interest up to study end. This trial is registered at ClinicalTrials.gov (NCT03276962) and is complete. FINDINGS: Between Sept 28, 2017, and Sept 25, 2018, 2157 children were enrolled, of whom 1609 were randomly assigned (322 to each RTS,S group and 321 to the control group). Of these 1609 children, 1500 received at least one study vaccine dose (exposed set), and 1333 were included in the per-protocol set for efficacy. Among children in the exposed set, to month 50, vaccine efficacy against all episodes of clinical malaria was 36% (95% CI 19-50), 51% (37-61), 43% (28-55), and 41% (26-53) in groups R012-20, R012-14-26-38, Fx012-14-26-38, and Fx017-20-32, respectively (p<0·001 for all). The numbers of cases averted per 1000 RTS,S full-dose equivalents were 353 (R012-20 group), 544 (R012-14-26-38 group), 1151 (Fx012-14-26-38 group), and 1134 (Fx017-20-32 group). Vaccine efficacy and impact and immune responses were maintained over 50 months of follow-up in groups who received additional vaccine doses after the fourth dose. The vaccine was well tolerated; only five serious adverse events were considered to be related to vaccination. There were no deaths considered to be related to vaccination. INTERPRETATION: All RTS,S regimens provided substantial protection against clinical malaria, with additional yearly doses maintaining vaccine efficacy and impact up to 50 months. Using fractional-dose regimens could increase the availability of RTS,S and reduce vaccination cost. FUNDING: GSK; PATH (through the Bill & Melinda Gates Foundation and the German Federal Ministry of Education and Research).
引用
- Osei-Tutu L, Kariuki SK, Lee CK, et al. Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial. Lancet Glob Health. 2025. PMID: 40975080. doi:10.1016/S2214-109X(25)00272-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。